eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2025-12-30 18 4 2922 2932 10.13005/bpj/3305 68730 article Sireesha Kalva 1 Sandeep Nayani 2 Kandregula Keerthika 3 Kavati Supriya 3 Tanzeel Fathima 3 Syeda Nusrath Fathima 3 Department of Pharm D, Sri Venkateshwara College of Pharmacy, Osmania University, Madhapur, Hyd., India. Department of Neurology, Apollo Hospital, Hyd., India. Department of Pharm D, Sri Venkateshwara College of Pharmacy, Osmania University, Madhapur, Hyd., India. Epilepsy, ranking as the second leading neurological cause of reduced disability-adjusted life years, underscores the necessity for effective long-term anti-epileptic drug therapy. Levetiracetam (Livipil), a newer anti-seizure medication, has gained prominence for its broad-spectrum efficacy in treating symptomatic and idiopathic epilepsy, offering pharmacokinetic advantages and a wide therapeutic range. Despite its efficacy, levetiracetam usage has been associated with behavioural side effects, including irritability, agitation, and aggression. Our study aims to conduct a comprehensive evaluation of the safety profile of levetiracetam in adults undergoing epilepsy therapy, focusing on the prevalence of adverse events, behavioural alterations, cognition abnormalities, and dose-dependent effects. A comprehensive evaluation was undertaken at Apollo Hospital, involving 100 patients receiving levetiracetam therapy, to assess psychotic adverse events associated with the medication. This rigorous methodology ensured a comprehensive understanding of the potential psychological effects of levetiracetam treatment in the patient cohort. Our study of 100 patients on levetiracetam highlighted several significant adverse effects, including changes in social behavior, depression, somnolence, anxiety, and cognitive impairment. Notably, 76% of patients showed changes in social behavior, while 78% reported depression. Somnolence affected all participants, impairing daily activities. Anxiety was present in 20% of patients, and 79% experienced varying degrees of cognitive impairment. We can conclude that despite of some consistency with existing literature, further research is needed to understand the underlying mechanisms and develop strategies to mitigate these adverse effects. https://biomedpharmajournal.org/vol18no4/incidence-of-psychiatric-adverse-events-with-levetiracetam-in-epilepsy-patients-in-india/ Adverse event Epilepsy Levetiracetam Neurological Cause Psychological effects Somnolence